Health
Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas – News-Medical.Net
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the…
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah™, researchers in Penn’s Abramson Cancer Center reported today in the New England Journal of Medicine. The findings represent the longest follow-up, published data to date for CAR T cell therapies approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory…
-
General14 hours agoWoman in her 20s dies after dog attack in Western Australia’s north
-
General21 hours agoGold Coast warned it faces traffic gridlock without major shift to public transport
-
Noosa News23 hours agoDicky Bill salad greens farms enter administration with 180 job cuts just before Christmas
-
Noosa News13 hours agoLuxury caravan manufacturer Zone RV collapses into administration